三阴性乳腺癌治疗进展

发布时间：2018-08-26 12:21

【摘要】：乳腺癌是全世界最常见的一种女性恶性肿瘤。三阴性乳腺癌是指雌激素受体、孕激素受体和人表皮生长因子受体2的表达均为阴性的乳腺癌,约占所有乳腺癌病理类型的15%~20%。三阴性乳腺癌的预后差、复发转移率高、死亡率高,已成为近年来乳腺癌研究和关注的焦点。目前针对乳腺癌的治疗手段包括手术治疗、新辅助化疗、辅助化疗、内分泌治疗和靶向治疗等。由于三阴性乳腺癌患者缺少雌激素受体、孕激素受体和人表皮生长因子受体2的表达,因此患者无法从针对乳腺癌的内分泌治疗及抗人表皮生长因子受体2的靶向治疗中获益。化疗是目前较推荐的三阴性乳腺癌治疗方法。许多化疗方案及新型的化疗药物也正在探索之中。本文对三阴性乳腺癌的化疗、内分泌治疗、靶向治疗和免疫治疗的研究进展进行综述。
[Abstract]:Breast cancer is the most common malignant tumor in women in the world. Triple negative breast cancer refers to breast cancer with negative expression of estrogen receptor progesterone receptor and human epidermal growth factor receptor 2 which accounts for 15% 20% of all pathological types of breast cancer. The poor prognosis, high recurrence and metastasis rate and high mortality of triple negative breast cancer have become the focus of breast cancer research in recent years. Current treatments for breast cancer include surgical treatment, neoadjuvant chemotherapy, endocrine therapy and targeted therapy. Due to the lack of estrogen receptor progesterone receptor and human epidermal growth factor receptor 2 expression in triple-negative breast cancer patients can not benefit from endocrine therapy for breast cancer and targeted therapy against human epidermal growth factor receptor 2. Chemotherapy is currently recommended for triple negative breast cancer treatment. Many chemotherapy schemes and new chemotherapeutic drugs are also being explored. This article reviews the advances in chemotherapy, endocrine therapy, targeted therapy and immunotherapy for triple-negative breast cancer.
【作者单位】：天津医科大学肿瘤医院乳腺肿瘤内科国家肿瘤临床研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心;
【基金】：国家自然科学基金资助项目(编号:81302080) 国家科技支撑计划资助项目(编号:2015BAI12B15)~~
【分类号】：R737.9

【相似文献】